Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain as a new driver in restoring the normal vaginal microbiota: A randomized, double-blind, placebo-controlled clinical trial
- 2023-01-09
- RCT · n = 60
- Frontiers in Surgery 9
- A. Rapisarda
- A. Pino
- Raffaela Luisa Grimaldi
- C. Caggia
- C. Randazzo
- A. Cianci
- PubMed: 36700035
- DOI: 10.3389/fsurg.2022.1075612
- High evidence
The oral consumption of the potential probiotic L. rhamnosus CA15 (DSM 33960) strain determined a significant improvement of both clinical signs and symptoms not only 10 days after the start of the treatment (T1) but also 30 days after the end of the treatment (T2).
- Effect
- Beneficial
- Effect size
- Large
- Significant
- Yes